Evidence map›Paper›PMID 40437918›Full record

ArticleEuropean journal of breast health2025

Evaluation of Tissue Expression of HMBG1 Protein in Patients With Breast Cancer.

Gülden Diniz, İsmail Güzeliş, Dudu Solakoğlu Kahraman, Duygu Ayaz, Umut Varol, Mustafa Değirmenci

Abstract read
In one paragraph

Article in European journal of breast health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gülden DinizDepartment of Pathology, İzmir Democracy University, Buca Seyfi Demirsoy Training and Research Hospital, İzmir, Türkiye.ORCID 0000-0003-1512-7584
İsmail GüzelişDepartment of Pathology, İzmir Democracy University, Buca Seyfi Demirsoy Training and Research Hospital, İzmir, Türkiye.ORCID 0000-0002-2309-4404
Dudu Solakoğlu KahramanDepartment of Pathology, İzmir Tepecik Education and Research Hospital, University of Health Sciences Türkiye, İzmir, Türkiye.ORCID 0000-0002-4126-5326
Duygu AyazDepartment of Pathology, İzmir Tepecik Education and Research Hospital, University of Health Sciences Türkiye, İzmir, Türkiye.ORCID 0000-0002-2202-2732
Umut VarolDepartment of Medical Oncology, İzmir Democracy University Faculty of Medicine, İzmir, Türkiye.ORCID 0000-0002-2288-9475
Mustafa DeğirmenciDepartment of Medical Oncology, İzmir Tepecik Education and Research Hospital, University of Health Sciences Türkiye, İzmir, Türkiye.ORCID 0000-0001-6988-9205

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: High mobility group box 1 (HMGB1) is a nonhistone chromatin-associated protein involved in chromatin remodeling, transcription, DNA replication, and repair. The purpose of this study was to assess the relationship between tissue expression of HMGB1, clinical outcomes, and histopathological characteristics in patients with breast cancer. Materials and Methods: The study included 282 patients with breast cancer. An Results: Overexpression of HMGB1 was found in tumor cells of 123 (43.6%) patients. HMGB1 was only expressed in the nucleus in most tumors (88.7%), while in 32 (11.3%) tumors HMBG1 expression was cytoplasmic and/or extracellular. Severe inflammatory infiltration of the peritumoral stroma was observed in 76 (27%) patients. There was a correlation between remarkable inflammatory cell infiltration in the tumor microenvironment and HMGB1 overexpression, regardless of the molecular subtype, as well as the extranuclear location of HMGB1 expression ( Conclusion: The proportion of breast cancer patients with HMGB1 expression was lower in the present study than that reported previously. Furthermore, we did not detect a relationship between HMGB1 expression and prognosis. However, the relationship between HMGB1 expression and prognosis had been previously reported only in aggressive breast cancers. It is suggested that understanding the significance of HMGB1 expression in breast cancer may open new treatment opportunities, especially in aggressive and/or triple negative tumors.

Indexed as

Breast cancerhigh mobility group box-1HMGB1 proteintissue expression

Identifiers

PMID40437918
PMCPMC12462726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.